News | Cardiac Diagnostics | October 20, 2017

American Heart Association, Verily and AstraZeneca Launch One Brave Idea Science Innovation Center

Boston facility will provide testing ground for researchers to collaborate on “early warning system” for coronary heart disease

American Heart Association, Verily and AstraZeneca Launch One Brave Idea Science Innovation Center

October 20, 2017 — The American Heart Association, Verily and AstraZeneca announced the opening of the One Brave Idea Science Innovation Center in Boston. The Center will be home to the Cardiovascular Medicine Innovation team, led by Calum MacRae, M.D., Ph.D., chief of cardiovascular medicine at Brigham and Women’s Hospital (BWH) who, leveraging the latest technologies and scientific advances, will continue their work for One Brave Idea, the $75 million research enterprise charged with bringing an end to coronary heart disease and its consequences.

The Science Innovation Center will provide an environment where world-renowned investigators can work quickly and collaboratively to discover new ways to identify the earliest markers of heart disease and develop strategies to stop the disease before an emergency happens. At the Innovation Center, they will have access to hospitals and clinics for real-world implementation, the engineering expertise of Massachusetts Institute of Technology (MIT), the clinical device expertise of BWH’s Next Generation Phenotyping Center, and the tech and medical innovation ecosystem in Cambridge and Boston. 

The One Brave Idea team represents a wide variety of specialties, including engineering and data science, and hails from institutions including BWH, MIT and Stanford.  They are working to create a coronary heart disease “early warning system” by examining what happens 10-20 years before risk factors typically appear.

“Facilitating collaboration among scientists is a cornerstone strategy for the American Heart Association and this team of multidisciplinary scientists aims to understand the earliest stages of the disease, figure out how it develops to prevent it from ever leading to heart attack and stroke,” said Nancy Brown, chief executive officer of the American Heart Association. “Through Verily’s informatic capabilities, AstraZeneca’s proprietary data and our evolving ecosystem of patient-centered research and scientific networks, the One Brave Idea research team will translate their findings into new prevention and treatment strategies.” 

“I’m immensely proud to lead this diverse team of investigators, who are committed to exploring and identifying the potential opportunities to prevent the development of heart disease. Creating multidisciplinary research teams to attack a problem from many angles is a model that we believe will ultimately have a significant impact on cardiovascular health,” said MacRae.

For more information: www.onebraveidea.com

Related Content

Insomnia Tied to Higher Risk of Heart Disease and Stroke

Image courtesy of the American Heart Association

News | Cardiac Diagnostics | August 19, 2019
People suffering from insomnia may have an increased risk of coronary artery disease, heart failure and stroke,...
Evolutionary Gene Loss May Help Explain Human Predisposition to Heart Attacks
News | Cardiac Diagnostics | July 29, 2019
The loss of a single gene two to three million years ago in our ancestors may have resulted in a heightened risk of...
U.S. Soldiers Have Worse Heart Health Than Civilians
News | Cardiac Diagnostics | June 06, 2019
Active duty Army personnel have worse cardiovascular health compared to people of similar ages in the civilian...
Late Dinner and No Breakfast Worsens Outcomes After Heart Attack
News | Cardiac Diagnostics | May 23, 2019
People who skip breakfast and eat dinner near bedtime have worse outcomes after a heart attack, according to research...
HRS Releases New Expert Consensus Statement on Arrhythmogenic Cardiomyopathy
News | Cardiac Diagnostics | May 14, 2019
The Heart Rhythm Society (HRS) released a first-of-its-kind consensus statement with guidance on the evaluation and...
New Best Practices Help Manage Heart Attack Patients Without Significant Signs
News | Cardiac Diagnostics | April 15, 2019
For the first time in the United States, doctors with the American Heart Association (AHA) have outlined best practices...
The most recent U.S. Food and Drug Administration (FDA) clearance was Siemens Healthineers high-sensitivity troponin I assays (TnIH) for the Atellica IM and ADVIA Centaur XP/XPT in vitro diagnostic analyzers. The test helps in the early diagnosis of myocardial infarctions without the need for serial tropic testing. The time to first results is 10 minutes.

The most recent U.S. Food and Drug Administration (FDA) clearance was Siemens Healthineers high-sensitivity troponin I assays (TnIH) for the Atellica IM and ADVIA Centaur XP/XPT in vitro diagnostic analyzers. The test helps in the early diagnosis of myocardial infarctions without the need for serial tropic testing. The time to first results is 10 minutes. 

Feature | Cardiac Diagnostics | March 22, 2019 | Linda C. Rogers, Ph.D.
Troponins are a family of proteins found in skeletal and heart (cardiac) muscle fibers that produce muscular contract
ACC/AHA Update Guidance for Preventing Heart Disease; Stroke
Feature | Cardiac Diagnostics | March 18, 2019
The choices we make every day can have a lasting effect on our heart and vascular health. Adopting a heart healthy...
AHA Statement Warns Hookah Smoking May Harm the Heart
News | Cardiac Diagnostics | March 08, 2019
Smoking tobacco in waterpipes, more commonly known as hookahs, results in inhaling toxic chemicals, often at levels...
Overlay Init